Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AtriCure, Inc. stock logo
ATRC
AtriCure
$22.00
+6.3%
$27.82
$20.19
$59.61
$1.05B1.41712,863 shs569,463 shs
Atrion Co. stock logo
ATRI
Atrion
$427.80
+4.3%
$417.97
$274.98
$602.59
$752.93M0.6219,401 shs22,463 shs
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
$20.00
$19.98
$12.26
$20.57
$843.96M0.74765,906 shs4,300 shs
Glaukos Co. stock logo
GKOS
Glaukos
$107.64
+0.7%
$94.66
$54.38
$110.73
$5.42B1.08643,878 shs242,276 shs
Luminex Co. stock logo
LMNX
Luminex
$36.99
$36.90
$20.61
$41.69
$1.75B0.56873,093 shsN/A
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AtriCure, Inc. stock logo
ATRC
AtriCure
+6.33%-0.99%-20.32%-33.17%-55.11%
Atrion Co. stock logo
ATRI
Atrion
+4.30%+3.10%-3.16%+12.77%-23.98%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.00%0.00%0.00%0.00%0.00%
Glaukos Co. stock logo
GKOS
Glaukos
+0.68%+2.39%+6.37%+11.85%+81.92%
Luminex Co. stock logo
LMNX
Luminex
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AtriCure, Inc. stock logo
ATRC
AtriCure
3.1095 of 5 stars
4.52.00.00.01.82.50.6
Atrion Co. stock logo
ATRI
Atrion
1.8659 of 5 stars
0.01.02.50.02.83.31.3
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
N/AN/AN/AN/AN/AN/AN/AN/A
Glaukos Co. stock logo
GKOS
Glaukos
3.9688 of 5 stars
2.43.00.04.43.72.50.6
Luminex Co. stock logo
LMNX
Luminex
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AtriCure, Inc. stock logo
ATRC
AtriCure
3.00
Buy$49.78126.26% Upside
Atrion Co. stock logo
ATRI
Atrion
N/AN/AN/AN/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
N/AN/AN/AN/A
Glaukos Co. stock logo
GKOS
Glaukos
2.82
Moderate Buy$108.640.93% Upside
Luminex Co. stock logo
LMNX
Luminex
N/AN/AN/AN/A

Current Analyst Ratings

Latest CSII, GKOS, ATRI, ATRC, and LMNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2024
Glaukos Co. stock logo
GKOS
Glaukos
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$84.00 ➝ $125.00
5/2/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$57.00 ➝ $49.00
5/2/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.00
5/2/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$46.00 ➝ $40.00
5/2/2024
Glaukos Co. stock logo
GKOS
Glaukos
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$107.00 ➝ $112.00
5/2/2024
Glaukos Co. stock logo
GKOS
Glaukos
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$108.00 ➝ $110.00
5/2/2024
Glaukos Co. stock logo
GKOS
Glaukos
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$120.00 ➝ $125.00
5/2/2024
Glaukos Co. stock logo
GKOS
Glaukos
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$103.00 ➝ $110.00
5/2/2024
Glaukos Co. stock logo
GKOS
Glaukos
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$108.00 ➝ $113.00
4/23/2024
AtriCure, Inc. stock logo
ATRC
AtriCure
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$32.00
4/11/2024
Glaukos Co. stock logo
GKOS
Glaukos
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$85.00 ➝ $100.00
(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AtriCure, Inc. stock logo
ATRC
AtriCure
$414.60M2.53N/AN/A$9.84 per share2.24
Atrion Co. stock logo
ATRI
Atrion
$169.33M4.45$20.22 per share21.16$138.02 per share3.10
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
$239.84M3.52N/AN/A$6.12 per share3.27
Glaukos Co. stock logo
GKOS
Glaukos
$326.43M16.61N/AN/A$9.46 per share11.38
Luminex Co. stock logo
LMNX
Luminex
$417.40M4.19$1.12 per share32.98$11.13 per share3.32

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AtriCure, Inc. stock logo
ATRC
AtriCure
-$30.44M-$0.80N/AN/AN/A-8.98%-7.85%-6.05%7/23/2024 (Estimated)
Atrion Co. stock logo
ATRI
Atrion
$19.41M$11.0338.79N/A11.46%8.07%7.37%5/13/2024 (Estimated)
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
-$36.93M-$0.97N/AN/AN/A-15.79%-15.39%-11.93%N/A
Glaukos Co. stock logo
GKOS
Glaukos
-$134.66M-$2.88N/AN/AN/A-43.15%-24.69%-12.27%8/7/2024 (Estimated)
Luminex Co. stock logo
LMNX
Luminex
$15.17M$0.3272.5330.83N/A5.39%4.66%2.91%N/A

Latest CSII, GKOS, ATRI, ATRC, and LMNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024Q1 2024
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.23-$0.25-$0.02-$0.22$106.86 million$108.90 million      
5/1/2024Q1 2024
Glaukos Co. stock logo
GKOS
Glaukos
-$0.58-$0.70-$0.12-$0.58$79.60 million$85.60 million    
2/29/2024Q4 2023
Atrion Co. stock logo
ATRI
Atrion
N/A$3.65+$3.65$3.65N/A$43.58 million
2/21/2024Q4 2023
Glaukos Co. stock logo
GKOS
Glaukos
-$0.56-$0.63-$0.07-$0.51$81.00 million$82.40 million    
2/15/2024Q4 2023
AtriCure, Inc. stock logo
ATRC
AtriCure
-$0.22-$0.21+$0.01-$0.21$103.68 million$106.50 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AtriCure, Inc. stock logo
ATRC
AtriCure
N/AN/AN/AN/AN/A
Atrion Co. stock logo
ATRI
Atrion
$8.802.06%+9.65%79.78%21 Years
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
N/AN/AN/AN/AN/A
Glaukos Co. stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
Luminex Co. stock logo
LMNX
Luminex
$0.401.08%N/A125.00%N/A

Latest CSII, GKOS, ATRI, ATRC, and LMNX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/27/2024
Atrion Co. stock logo
ATRI
Atrion
Quarterly$2.202.42%3/14/20243/15/20243/29/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AtriCure, Inc. stock logo
ATRC
AtriCure
0.16
4.00
2.83
Atrion Co. stock logo
ATRI
Atrion
N/A
9.09
2.57
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.08
6.04
4.92
Glaukos Co. stock logo
GKOS
Glaukos
0.78
5.38
4.68
Luminex Co. stock logo
LMNX
Luminex
0.52
8.37
6.08

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
99.11%
Atrion Co. stock logo
ATRI
Atrion
66.19%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
86.61%
Glaukos Co. stock logo
GKOS
Glaukos
99.04%
Luminex Co. stock logo
LMNX
Luminex
87.76%

Insider Ownership

CompanyInsider Ownership
AtriCure, Inc. stock logo
ATRC
AtriCure
3.20%
Atrion Co. stock logo
ATRI
Atrion
22.82%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
3.80%
Glaukos Co. stock logo
GKOS
Glaukos
6.40%
Luminex Co. stock logo
LMNX
Luminex
6.60%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AtriCure, Inc. stock logo
ATRC
AtriCure
1,20047.59 million46.07 millionOptionable
Atrion Co. stock logo
ATRI
Atrion
7121.76 million1.36 millionNot Optionable
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
78042.20 million40.59 millionOptionable
Glaukos Co. stock logo
GKOS
Glaukos
90750.37 million46.98 millionOptionable
Luminex Co. stock logo
LMNX
Luminex
1,32547.31 millionN/AOptionable

CSII, GKOS, ATRI, ATRC, and LMNX Headlines

SourceHeadline
Flash News: OKX Wallet Web Extension Expands to Include Luminex AccessFlash News: OKX Wallet Web Extension Expands to Include Luminex Access
finance.yahoo.com - April 18 at 7:42 AM
Luminex-Puritas JV secures Mallavi Urban Water Supply Scheme contract in MullaitivuLuminex-Puritas JV secures Mallavi Urban Water Supply Scheme contract in Mullaitivu
ft.lk - March 24 at 4:40 PM
ERS electronic introduces the first semi-automatic machine of its Luminex product line featuring groundbreaking PhotoThermal debonding technologyERS electronic introduces the first semi-automatic machine of its Luminex product line featuring groundbreaking PhotoThermal debonding technology
finance.yahoo.com - March 13 at 8:18 AM
Adventus and Luminex Announce Merger to Create a Growth-Focused Copper-Gold Company in EcuadorAdventus and Luminex Announce Merger to Create a Growth-Focused Copper-Gold Company in Ecuador
finance.yahoo.com - November 21 at 6:05 PM
Luminex Resources Corp (LR)Luminex Resources Corp (LR)
investing.com - October 28 at 5:46 AM
Luminex Resources Announces Excellent Metallurgical Results at Cuyes WestLuminex Resources Announces Excellent Metallurgical Results at Cuyes West
juniorminingnetwork.com - September 27 at 10:41 AM
Luminex Announces Excellent Metallurgical Results at Cuyes WestLuminex Announces Excellent Metallurgical Results at Cuyes West
newswire.ca - September 27 at 10:41 AM
Streck Quality Controls for DiaSorins Luminex Sepsis Tests Receive FDA ClearanceStreck Quality Controls for DiaSorin's Luminex Sepsis Tests Receive FDA Clearance
360dx.com - September 25 at 3:28 PM
Luminex (LMNX) Receives FDA Approval for NxTAG RPPLuminex (LMNX) Receives FDA Approval for NxTAG RPP
finance.yahoo.com - September 24 at 1:13 AM
Luminex Has Entered into Discussions with Anglo American to Amend the Terms of the Pegasus Earn-InLuminex Has Entered into Discussions with Anglo American to Amend the Terms of the Pegasus Earn-In
prnewswire.com - September 20 at 7:04 AM
Luminex Reaches Agreement with a Second Association of Artisanal Miners Around Condor NorthLuminex Reaches Agreement with a Second Association of Artisanal Miners Around Condor North
finance.yahoo.com - September 8 at 8:55 AM
Stenograph Announces the Release of the Bordeaux Luminex IIStenograph Announces the Release of the Bordeaux Luminex II
marketscale.com - September 6 at 5:54 PM
Luminex moots JV with PuritasLuminex moots JV with Puritas
ft.lk - September 5 at 8:57 PM
Luminex Announces an Update on the Pegasus Earn-inLuminex Announces an Update on the Pegasus Earn-in
finance.yahoo.com - August 23 at 6:19 PM
Luminex reaches ‘historic’ agreement with informal miners around Ecuador gold projectLuminex reaches ‘historic’ agreement with informal miners around Ecuador gold project
mining.com - August 22 at 9:51 PM
Luminex Reaches Historic Agreement with Informal Miners Around Condor NorthLuminex Reaches Historic Agreement with Informal Miners Around Condor North
finance.yahoo.com - August 21 at 7:42 AM
New BRC69 Token Standard Promises 90% Savings for Bitcoin’s Ordinal InscriptionsNew BRC69 Token Standard Promises 90% Savings for Bitcoin’s Ordinal Inscriptions
news.bitcoin.com - July 5 at 2:07 AM
Bitcoin Ordinals Launchpad Luminex Announces BRC-69 Standard to Simplify Recursive InscriptionsBitcoin Ordinals Launchpad Luminex Announces BRC-69 Standard to Simplify Recursive Inscriptions
coinspeaker.com - July 4 at 9:02 AM
Stenograph Announces the Release of the Graphite Luminex IIStenograph Announces the Release of the Graphite Luminex II
marketscale.com - June 21 at 11:38 PM
Luminex Resources drill results reveal high-grade intercept in New Breccia Pipe at Cuyes WestLuminex Resources drill results reveal high-grade intercept in New Breccia Pipe at Cuyes West
finance.yahoo.com - May 30 at 3:02 PM
Luminex Resources drill results showing high-grade intercept in New Breccia Pipe at Cuyes WestLuminex Resources drill results showing high-grade intercept in New Breccia Pipe at Cuyes West
proactiveinvestors.com - May 29 at 2:56 PM
Global Chemiluminescence Immunoassay (Clia) Analyzers Market ... - Digital JournalGlobal Chemiluminescence Immunoassay (Clia) Analyzers Market ... - Digital Journal
news.google.com - May 14 at 10:05 AM
Molecular Biology Analyzers Market: Size & Trends Shows a Rapid ... - Cottonwood Holladay JournalMolecular Biology Analyzers Market: Size & Trends Shows a Rapid ... - Cottonwood Holladay Journal
news.google.com - May 13 at 1:37 AM
Flow Cytometer System Market Size, Development Data, Growth ... - StreetBuzzFlow Cytometer System Market Size, Development Data, Growth ... - StreetBuzz
news.google.com - May 13 at 1:37 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AtriCure logo

AtriCure

NASDAQ:ATRC
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Atrion logo

Atrion

NASDAQ:ATRI
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. Its cardiovascular products comprise Myocardial Protection System that delivers fluids and medications, and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. The company's ophthalmic products consist of a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. It manufactures products for safe needle and scalpel blade containment; inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.
Cardiovascular Systems logo

Cardiovascular Systems

NASDAQ:CSII
Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St. Paul, MN.
Glaukos logo

Glaukos

NYSE:GKOS
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Luminex logo

Luminex

NASDAQ:LMNX
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.